Hugo Antonio Romo Rubio: A New Paradigm in Treatment for Hemophilia A from FRONTIERS2 Phase 3 Study
Hugo Antonio Romo Rubio, Pediatric Oncologist and Faculty Member at Nuevo Hospital Civil Court of Guadalajara, Presided over by Dr. Juan I. Menchaca, shared on LinkedIn about a recent article by Maria Elisa Mancuso et al, published in NEJM:
”Hemophilia A: The FRONTIERS2 Phase 3 Study. Mim8 (Denecimig) Prophylaxis – A New Paradigm in Treatment.
The landscape of Hemophilia A management is evolving.
Results from the ‘FRONTIERS2 Phase 3 trial’ highlight the transformative potential of ‘Mim8 (denecimig)‘, a next-generation bispecific antibody, as a cornerstone for prophylactic care.
Key Highlights from the Study:
- Superior Efficacy: Mim8 prophylaxis demonstrated clear superiority in reducing bleeding episodes compared to both on-demand treatment and prior prophylaxis with coagulation factor concentrates.
- Drastic Reduction in ABR: Patients treated with Mim8 experienced up to a 98.7% reduction in the Annualized Bleeding Rate (ABR) for treated bleeds when compared to the on-demand group.
- Broad Clinical Utility: The drug proved effective across the board, including patients with and without inhibitors, as well as across varying degrees of Hemophilia A severity.
- Robust Safety Profile: Mim8 maintained a favorable safety profile throughout the study, with no reported thromboembolic events, deaths, or neutralizing antibodies.
- Superior Bleed Control: An impressive majority of participants – ranging from 64% to 95% – remained entirely free of treated bleeds during the 26-week trial period.
- Optimized Dosing Regimen: The tiered dosing model simplifies administration through low-volume subcutaneous injections. With weekly or monthly frequency options, it significantly reduces the overall treatment burden for patients.
This data reinforces Mim8’s potential to redefine the standard of care, offering patients a more flexible and highly effective path toward a zero-bleed reality.”
Title: Mim8 Bispecific Antibody Prophylaxis in Hemophilia A with or without Inhibitors
Authors: Maria Elisa Mancuso, Anthony K.C. Chan, Chandrakala Shanmukhaiah, Chuhl Joo Lyu, Joanna Zdziarska, Johnny Mahlangu, Lize F.D. van Vulpen, Pratima Chowdary, Renchi Yang, Steven R. Lentz, Tadashi Matsushita, Wan Hui Ong Clausen, Ilgiz Rakhmatullin, Johannes Oldenburg for the FRONTIER2 Investigators

Stay updated on all scientific advances with Hemostasis Today.
-
Nov 17, 2026, 23:45Cajetan Reichardt: LAAO vs. OAC in AF – Balancing Nonprocedural Bleeding and Ischemic Stroke Risk
-
Nov 17, 2026, 23:42Brian Tegtmeyer: Expanding Pre-Hospital Administration of Low-Titer O Positive Whole Blood
-
Nov 17, 2026, 23:41Mansi Kala: Advancing Hematology – From Evidence to Clinical Excellence
-
Nov 17, 2026, 23:40Nathan Connell: Registered for the WFH Comprehensive Care Summit 2027 in Prague
-
Nov 17, 2026, 23:38Yaariv Khaykin: Does Reducing AF Burden After Ablation Change the Need for Anticoagulation?
-
Nov 17, 2026, 23:38Amos Gitonga Mbaabu: Strengthening Care and Advocacy for Haemophilia and SCD across Southern Africa
-
Nov 17, 2026, 23:35Muhammad Sameed Altaf: A Decade of Working Together for Thalassemia Awareness and Patient Support
-
Nov 17, 2026, 23:34Ahmed Bennis: Is Aspirin Therapy Enough for VTE Prevention After Arthroplasty?
-
Nov 17, 2026, 23:33Remi Remakanth: The Role of Transfusion Medicine in HLA Antibody Testing and Transplant Desensitization